Kezar Life Sciences (NASDAQ:KZR) Posts Earnings Results

Kezar Life Sciences (NASDAQ:KZR) released its quarterly earnings results on Monday. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.20, Zacks reports.

Kezar Life Sciences Price Performance

Shares of NASDAQ:KZR traded up $0.13 during mid-day trading on Monday, reaching $7.42. 616,015 shares of the company traded hands, compared to its average volume of 127,532. The company’s 50 day moving average price is $7.09 and its 200-day moving average price is $6.55. The firm has a market cap of $54.78 million, a PE ratio of -0.97 and a beta of 0.40. Kezar Life Sciences has a 52 week low of $3.53 and a 52 week high of $7.55.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Kezar Life Sciences in a research note on Friday. Four research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $6.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KZR. Landscape Capital Management L.L.C. bought a new position in shares of Kezar Life Sciences during the 3rd quarter valued at approximately $51,000. Woodline Partners LP bought a new position in shares of Kezar Life Sciences during the 1st quarter valued at approximately $125,000. Torno Capital LLC bought a new position in shares of Kezar Life Sciences during the 4th quarter valued at approximately $126,000. Dimensional Fund Advisors LP grew its stake in shares of Kezar Life Sciences by 14.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company’s stock valued at $167,000 after acquiring an additional 3,312 shares during the period. Finally, State Street Corp grew its stake in shares of Kezar Life Sciences by 28.4% during the 4th quarter. State Street Corp now owns 27,093 shares of the company’s stock valued at $170,000 after acquiring an additional 6,000 shares during the period. 67.90% of the stock is currently owned by institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.